- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
Patent holdings for IPC class A61K 31/5375
Total number of patents in this class: 1540
10-year publication summary
|
131
|
108
|
116
|
119
|
118
|
119
|
118
|
95
|
86
|
19
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 5080 |
22 |
| Novartis AG | 11238 |
19 |
| Supernus Pharmaceuticals, Inc. | 133 |
17 |
| Allergan, Inc. | 2600 |
16 |
| Axsome Therapeutics, Inc. | 213 |
14 |
| Arbor Pharmaceuticals, LLC | 82 |
13 |
| Astellas Pharma Inc. | 1145 |
12 |
| vTv Therapeutics LLC | 159 |
12 |
| F. Hoffmann-La Roche AG | 7958 |
11 |
| Aeromics, Inc. | 25 |
11 |
| Mitsubishi Tanabe Pharma Corporation | 579 |
11 |
| Gilead Sciences, Inc. | 1879 |
10 |
| Global Blood Therapeutics, Inc. | 180 |
10 |
| Zogenix International Limited | 77 |
10 |
| Apnimed, Inc. (Delaware) | 35 |
10 |
| Boehringer Ingelheim International GmbH | 4629 |
9 |
| Centre National de La Recherche Scientifique | 9632 |
9 |
| Dainippon Sumitomo Pharma Co., Ltd. | 234 |
9 |
| Epizyme, Inc. | 383 |
9 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
9 |
| Other owners | 1297 |